Tan, D., Ng, M., Subbiah, V., Messersmith, W., Teneggi, V., Diermayr, V., … Matter, A. (2018). Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours. In Annals of oncology : official journal of the European Society for Medical Oncology (Vol. 29, pp. ix23–ix24). https://doi.org/10.1093/annonc/mdy430.002

Tan, D., M. Ng, V. Subbiah, W. Messersmith, V. Teneggi, V. Diermayr, K. Ethirajulu, et al. “Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours.” In Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29:ix23–24, 2018. https://doi.org/10.1093/annonc/mdy430.002.

Tan D, Ng M, Subbiah V, Messersmith W, Teneggi V, Diermayr V, et al. Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018. p. ix23–4.

Tan, D., et al. “Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, 2018, pp. ix23–24. Scopus, doi:10.1093/annonc/mdy430.002.

Tan D, Ng M, Subbiah V, Messersmith W, Teneggi V, Diermayr V, Ethirajulu K, Yeo P, Gan BH, Lee LH, Blanchard S, Nellore R, Yasin M, Umrani D, Lee MA, Hill J, Madan B, Virshup D, Matter A. Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours. Annals of oncology : official journal of the European Society for Medical Oncology. 2018. p. ix23–ix24.